EP1437137B1 - Drugs comprising combination of antithrombotic agent with pyrazolone derivative - Google Patents

Drugs comprising combination of antithrombotic agent with pyrazolone derivative Download PDF

Info

Publication number
EP1437137B1
EP1437137B1 EP02760833A EP02760833A EP1437137B1 EP 1437137 B1 EP1437137 B1 EP 1437137B1 EP 02760833 A EP02760833 A EP 02760833A EP 02760833 A EP02760833 A EP 02760833A EP 1437137 B1 EP1437137 B1 EP 1437137B1
Authority
EP
European Patent Office
Prior art keywords
group
carbon atoms
pyrazolin
methyl
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02760833A
Other languages
German (de)
French (fr)
Other versions
EP1437137A1 (en
EP1437137A4 (en
Inventor
Keiichi TESSEIKAI NEUROSURGICAL HOSPITAL YAMADA
Katsumi c/o MITSUBISHI PHARMA CORP. KURITA
Tadashi c/o MITSUBISHI PHARMA CORP. TANAKA
Masahiko c/o MITSUBISHI PHARMA CORP. TANAKA
Jyunichi c/o MITSUBISHI PHARMA CORP. EGUCHI
Satoshi c/o MITSUBISHI PHARMA CORP. YUKI
Narihiko c/o MITSUBISHI PHARMA CORP. YOSHII
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of EP1437137A1 publication Critical patent/EP1437137A1/en
Publication of EP1437137A4 publication Critical patent/EP1437137A4/en
Application granted granted Critical
Publication of EP1437137B1 publication Critical patent/EP1437137B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms

Definitions

  • This invention relates to a drug comprising a combination of antithromotic agent with a pyrazolone derivative according to claim 1.
  • the present invention relates to the aforementioned combined drug which is useful for the remedy and/or prevention of various ischemic diseases.
  • an antithrombotic agent (a thrombolytic agent, an anticoagulant, a platelet aggregation inhibitory agent) has been used hereinbefore.
  • the remedy using such antithrombotic agent was given the priority to the treatment for the thrombus in blood vessel and the improvement of circulation.
  • the known antithrombotic agent includes a tissue plasmigogen activator (hereinafter sometimes referred to as t-PA), a urokinase (UK), heparin, argatroban, ozagral sodium, aspirin and ticlopidine and the like.
  • the antithrombotic agent is administered in large quantities or the administration of the antithrombotic agent is delayed, the conditions of the patient become worse by occurrence of the adverse effect of cerebral hemorrhage. Consequently, it cannot be said that there are few subjects to be solved.
  • Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), recently developed redical scavenger which was claimed in Japanese Patent Examined Publication (Kokoku) No. Hei. 4-35128 exhibits a free radical scavenging activity and an inhibiting activity against lipid peroxidation in cell membranes and the like. According to such activities, edaravone protects the nerve cell at the ischemic penumbra, and is able to keep the ischemic disorder to a minimum. The characteristics of edaravone includes no influence to the coagulation of blood and the aggregation of platelet and the like, and few hemorrhagic adverse effects.
  • MCI-186 3-methyl-1-phenyl-2-pyrazolin-5-one
  • Yong-Jian Jin et al., 2002 discloses the combined administration of argatroban and edaravone in a model of forebrain ischemia in gerbils. It is stated that a combination of these types of drugs may help to improve the outcomes after cerebral ischemia.
  • the subject to be solved of the present invention is to provide a drug for the remedy and/or prevention of ischemic diseases with less adverse effect, safety and having high clinical effects.
  • the present inventors have conducted various investigations to heighten the clinical effects accompanied with more high safety in the treatment of the aforementioned antithrombotic agent and found that the combination of tissue plasminogen activator with a pyrazolone derivative of the formula (I) can provides the drug for the remedy and/or prevention of ischemic diseases with less adverse effect, safety and having high clinical effects, and then completed the present invention.
  • the present invention provides a drug comprising a combination of tissue plasminogen activator with a pyrazolone derivative of the following formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
  • R 1 represents hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total
  • R 2 represents hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or a hydroxyalkyl group having 1 to 3 carbon atoms
  • R and R 2 is coupled together to form an alkylene group having 3 to 5 carbon atoms
  • R 3 represents hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, benzyl group, a nap
  • the present invention provides a combined drug to administer tissue plasminogen activator and the pyrazolone derivative of the aforementioned formula (I), simultaneously, separately or sequentially.
  • antithrombotic agent examples include the thrombolytic agent t-PA, an anticoagulant, and a platelet aggregation inhibitory agent.
  • An example of anticoagulants is antithrombin agent
  • an example of platelet aggregation inhibitory agents is a thromboxane synthetase inhibitor.
  • antithrombin agents for example, (2R, 4R)-4-methyl-1-[N 2 -((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (non-proprietary name: argatroban): and the concrete example of thromboxane synthetase inhibitors is sodium (E)-[p-(1H-imidazol-1-yl)phenyl]-2-propenoate (non-proprietary name: ozagrel sodium):
  • the antithrombotic agent of the present invention is t-PA.
  • the pyrazolone derivative of the formula (I) is preferably 3-methyl-1-phenyl-2-pyrazolin-5-one.
  • the combined drugs of the present invention can be preferably used for the remedy and/or prevention of ischemic diseases.
  • ischemic diseases include various ischemic diseases or various diseases caused thereby, more specifically, various cerebral diseases, for example, cerebrovascular disorders such as cerebral infraction and stroke, impairment of brain functions due to these cerebrovascular disorders, vascular dementia, and age-related damage to cerebrovascular tissue; various heart diseases caused by myocardial ischemia such as myocardial infarction and cardiac failure; and various peripheral circulatory disorders.
  • Preferred examples include nerve symptoms, daily behavior problems and functional disturbances, each in the acute stage of cerebral infarction; neurological symptoms (motor paralysis) in acute cerebral thrombosis (excluding lacunar infarction) within 48 hours from onset, disturbances against activities of daily living (walking, standing, sustaining the sitting position, eating); and dyskinesia associated with cerebral thrombosis (acute stage).
  • the present invention provides a remedial agent and/or preventive agent for ischemic diseases by administering tissue plasminogen activator and the pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, simultaneously, separately or sequentially.
  • tissue plasminogen activator which contains the pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
  • Another aspect of the present invention provides for use in a method of treating and/or preventing ischemic diseases, a pharmacologically effective amount of tissue plasminogen activator and a pharmacologically effective amount of a pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof to mammals inclusive of human beings, simultaneously, separately or sequentially.
  • the combined drugs of the present invention contain an antithrombotic agent and a pyrazolone derivative of the formula (I) defined in the present specification or a pharmaceutically acceptable salt thereof.
  • the antithrombotic agent used in the present invention includes a tissue plasminogen activator (t-PA).
  • Other agents include a urokinase (UK), heparin, argatroban, ozagrel sodium, aspirin, ticlopidine and the like.
  • antithrombotic agents include antithrombin agent and/or a thromboxane synthetase inhibitory agent and more concretely (2R, 4R)-4-methyl-1-[N 2 ((RS)-3-methyl-1,2,3,4- tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (argatroban) and/or sodium (E)-[p-(1H-imidazol-1-yl) phenyl]-2-propenoate (ozagrel sodium).
  • the compound of formula (I) used in the present invention may have the following chemical structures of formulae (I') and (I"). Consequently, the active ingredient of the present invention embraces the compounds of formulae (I') and (I")
  • the aryl group in the definition of R 1 includes phenyl group and a phenyl group substituted by a substituent such as methyl group, butyl group, methoxy group, butoxy group, chlorine atom and hydroxyl group and the like.
  • the alkyl group having 1 to 5 carbon atoms in the definition of R 1 , R 2 and R 3 includes methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group and the like.
  • the alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total in the definition of R 1 includes methoxycarbonylmethyl group, ethoxycarbonylmethyl group, propoxycarbonylmethyl group, methoxycarbonylethyl group, methoxycarbonylpropyl group and the like.
  • the aryloxy group is phenoxy group, p-methylphenoxy group, p-methoxyphenoxy group, p-chlorophenoxy group, p-hydroxyphenoxy group and the like
  • the arylmercapto group includes phenylmercapto group, p-methyl phenylmercapto group, p-methoxyphenylmercapto group, p-chlor phenylmercapto group, p-hydroxyphenylmercapto group and the like.
  • the hydroxyalkyl group having 1 to 3 carbon atoms in the definition of R 2 and R 3 includes hydroxymethyl group, 2-hydroxyethyl group, 3-hydroxypropyl group and the like.
  • the cycloalkyl group having 5 to 7 carbon atoms in the definition of R 3 is cyclopentyl group, cyclohexyl group, cycloheptyl group and the like.
  • the alkoxy group having 1 to 5 carbon atoms includes methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, pentyloxy group and the like
  • the alkoxycarbonyl group having 2 to 5 carbon atoms in total includes methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, butoxycarbonyl group and the like
  • the alkylmercapto group having 1 to 3 carbon atoms includes methylmercapto group, ethylmercapto group, propylmercapto group and the like
  • the alkylamino group having 1 to 4 carbon atoms includes methylamino group, ethylamino group, propylamino group, butylamino group and the like
  • the dialkylamino group having 2 to 8 carbon atoms in total includes dimethylamino group, diethylamino group, dipropylamino
  • the Examples of the compounds of formula (I) used in the present invention include, for example, the following compounds:
  • physiologically acceptable salt as well as a free form of the compound of formula (I) can be used.
  • physiologically acceptable salt includes a salt with a mineral acid such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid and the like; a salt of an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, glycolic acid, glucuronic acid, maleic acid, fumaric acid, oxalic acid, ascorbic acid, citric acid, salicylic acid, nicotinic acid, tartaric acid and the like; a salt with an alkaline metal such as sodium, potassium and the like, and a salt with an amine such as ammonia, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanol
  • the active ingredient of the drug of the present invention can be used as a hydrate of the compound of the aforementioned formula (I) or a physiologically acceptable salt thereof, and a solvate of the compound of the aforementioned formula (I) or a physiologically acceptable salt thereof.
  • a type of the solvent used to form a solvate is not specifically limited.
  • methanol, ethanol, ether, dioxane, tetrahydrofuran can be exemplified.
  • the compounds of the aforementioned formula (I) have one or more asymmetric carbons based on the type of the substituent, there may exist a stereoisomer such as an optical isomer or a diastereoisomer.
  • a stereoisomer in a pure form, any mixture of stereoisomers, a racemate and the like may also be used.
  • the compounds of formula (I) used in the present invention are known compounds and disclosed, for example, in Japanese Patent Examined Publication (Kokoku) No. Hei. 5-31523 , Japanese Patent Examined Publication (Kokoku) No. Hei. 5-35128 and the like.
  • the dose of tissue plasminogen activator used in the present invention is usually 0.01 to 100 mg/kg per day, preferably 0.1 to 10 mg/kg per day for the parenteral administration, and 1 to 1,000 mg/kg per day, preferably 0.5 to 50 mg/kg per day for the oral administration.
  • the aforementioned dose can be preferably administered once to three times a day.
  • the dose mentioned above may be suitably varied depending upon the age, and the severity and condition of the diseases.
  • the dose of the pyrazolone derivative of the formula (I) used in the present invention is usually 0.01 to 100 mg/kg per day, preferably 0.1 to 10 mg/kg per day for the parenteral administration, and 1 to 1,000 mg/kg per day, preferably 0.5 to 50 mg/kg per day for the oral administration.
  • the aforementioned dose can be preferably administered once to three times a day.
  • the dose mentioned above may be suitably varied depending upon the age, and the severity and condition of the diseases.
  • the combined drug of the present invention may be administered separately by formulating each of the antithrombotic agent and the pyrazolone derivatives of formula (I) into each of drugs.
  • the antithrombotic agent and the pyrazolone derivative of formula (I) can be administered simultaneously, separately or sequentially.
  • the antithrombotic agent and the pyrazolone derivative of formula (I) can be also administered by formulating them into a single formulation.
  • the antithrombotic agent and the pyrazolone derivative of formula (I), a physiologically acceptable salt thereof, or a hydrate or solvate thereof can be administered themselves, but usually and preferably administered by preparing a pharmaceutical composition containing the aforementioned substance as the active ingredient and a pharmacologically and pharmaceutically acceptable additive.
  • Such pharmacologically and pharmaceutically acceptable additive include, for example, an excipient, a disintegrator or a disintegration adjuvant agent, a binder, a lubricant, a coating agent, a pigment, a diluent, a base, a solvent or a solubilizer, an isotonic agent, a pH adjusting agent, a stabilizer, a propellant, and an adhesive.
  • an excipient such as glucose, lactose, D-mannitol, starch, or crystalline cellulose and the like; a disintegrator or a disintegration adjuvant agent such as carboxymethylcellulose, starch, or calcium carboxymethylcellulose and the like; a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, or gelatin and the like; a lublicant such as magnesium stearate or talc and the like; a coating agent such as hydroxypropylmethylcellulose, sucrose, polyethyleneglycol, or titanium oxide and the like; or a base such as vaseline, liquid paraffin, polyethyleneglycol, gelatin, kaolin, glycerin, purified water or a hard fat can be used.
  • an excipient such as glucose, lactose, D-mannitol, starch, or crystalline cellulose and the like
  • a disintegrator or a disintegration adjuvant agent such as carboxy
  • an additive for example, a solvent or a solubilizer such as distilled water for injection, physiological saline or propylene glycol that can constitute an aqueous injection or an injection that is dissolved when used; an isotonic agent such as glucose, sodium chloride, D-mannitol, glycerin and the like; or a pH adjusting agent such as an inorganic acid, an organic acid, an inorganic base or an organic base and the like.
  • a solvent or a solubilizer such as distilled water for injection, physiological saline or propylene glycol that can constitute an aqueous injection or an injection that is dissolved when used
  • an isotonic agent such as glucose, sodium chloride, D-mannitol, glycerin and the like
  • a pH adjusting agent such as an inorganic acid, an organic acid, an inorganic base or an organic base and the like.
  • the form of the drug of the present invention is not specifically limited, and may be any of the various forms that can be applied to the person skilled in the art.
  • the drug appropriate for oral administration for example, tablets, powders, granules, hard gelatin capsules, suppositories, or troches and the like can be prepared by using solid additives for pharmaceutical preparation, and for example, syrups, emulsions, soft gelatin capsules and the like can be prepared by using liquid additives for pharmaceutical preparation.
  • the pharmaceutical preparation suitable for parenteral administration injections, drip infusions, inhalants, percutaneous absorbents, trans-mucosal absorbents and the like can be prepared.
  • the aforementioned commercially available drug can be used as it is as the pyrazolone derivative of formula (I) for the combined drug of the present invention.
  • Grtpa registered trademark; manufactured and distributed by Mitsubishi Pharma Corporation
  • Xanbon registered trademark; manufactured and distributed by Kissei Pharmaceutical Co., Ltd.
  • Novastan registered trademark; manufactured and distributed by Mitsubishi Pharma Corporation
  • any pharmaceutical preparations containing t-PA, ozagrel sodium, argatroban as the active ingredient which are regardless of the manufacturing or distributing company can be used.
  • the t-PA-administered group prolonged the bleeding time significantly.
  • the t-PA- and edaravone-administered group did not have a significant influence on the bleeding time, compared with the edaravone-administered group. From this, it is apparent that edaravone can be used in combination with t-PA without causing any side effects.
  • Sodium ozagrel 80 mg of sodium ozagrel was dissolved in an adequate amount of an electrolyte solution or carbohydrate solution and the resulting solution was intravenously administered constantly for 2 weeks, twice daily, that is, in the morning and evening, each over 2 hours.
  • Argatroban For the first two days, 60 mg/120 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused constantly over 24 hours. For the following 5 days, 10 mg/20 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused twice daily, that is, in the morning and evening, each over 3 hours.
  • Sodium ozagrel + edaravone 80 mg of sodium ozagrel was dissolved in an adequate amount of an electrolyte solution or carbohydrate solution and the resulting solution was intravenously administered constantly for 2 weeks, twice daily, that is, in the morning and evening, each over 2 hours. At the same time, 30 mg/20 ml of edaravone was diluted with an adequate amount of physiological saline and the resulting solution was intravenously infused for 2 weeks, twice daily, that is, in the morning and evening, each over 20 minutes.
  • Argatroban + edaravone For the first two days, 60 mg/120 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused constantly over 24 hours. For the following 5 days, 10 mg/20 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused twice daily, that is, in the morning and evening, each over 3 hours; and at the same time, 30 mg/20 ml of edaravone was diluted with an adequate amount of physiological saline and the resulting solution was intravenously infused for 2 weeks twice daily, that is, in the morning and evening, each over 30 minutes.
  • Grade 0 no symptoms
  • Grade 1 some symptoms but non-significant disability (able to carry out all daily activities and affairs)
  • Grade 2 slight disability (unable to carry out all previous activities but able to look after own affairs without assistance)
  • Grade 3 moderate disability (requiring some help, but able to walk without assistance)
  • Grade 4 relatively severe disability (requiring assistance for walk or daily activities)
  • Grade 5 very severe disability (bedridden, incontinence and requiring constant nursing care and attention)
  • Grade 6 death.
  • Comparative Example 1 There is no difference between Comparative Example 1 and Comparative Example 2 except for the time of evaluation based on the modified ranking scale, that is, within one month after the initiation of administration in Comparative Example 1, while within three months in Comparative Example 2.
  • These results obtained in Comparative Example 1 and 2 were therefore compared, which has revealed that a ratio of Grade 0 was 35.3% when the antithrombotic agent was used alone and 0% when edaravone was used alone, while it was 55.0% when the antithrombotic agent and edaravone were used in combination. This suggests that combined use of the antithrombotic agent and edaravone brings not merely an additive effect but a synergistic effect, and function prognosis is good.
  • the pyrazolone derivatives used in the present invention can enhance the suppressing effects to the function disorder of the antithrombotic agent, suppress the aggravate of the symptoms caused by the side effects of the antithrombotic agent and reperfusion injuries to a minimum, and then bring the more safe clinical effects.
  • the combined drugs of the present invention are useful as the preventive and/or remedial medicament for various ischemic diseases or various diseases caused thereby, specifically various cerebral diseases, for example, cerebrovascular disorders such as cerebral infarction and stroke, impairment of brain functions due to these cerebrovascular disorders, vascular dementia, age-related damage to cerebrovascular tissues; various heart diseases caused by myocardial ischemia such as myocardial infarction and cardiac failure; and various peripheral circulatory disorders.
  • cerebrovascular disorders such as cerebral infarction and stroke
  • impairment of brain functions due to these cerebrovascular disorders vascular dementia, age-related damage to cerebrovascular tissues
  • various heart diseases caused by myocardial ischemia such as myocardial infarction and cardiac failure
  • peripheral circulatory disorders for example, cerebrovascular disorders such as cerebral infarction and stroke, impairment of brain functions due to these cerebrovascular disorders, vascular dementia, age-related damage to cerebrovascular tissues.
  • myocardial ischemia such as myocardial infarction and cardiac failure
  • peripheral circulatory disorders for example

Abstract

Composition for treating ischemic conditions comprises anti-thrombus agent (II) and pyrazolin-5-one or derivative : Composition contains an anti-thrombus agent (II) and pyrazolin-5-one or its derivatives of formula (I), or their salts, hydrates and solvates. [Image] R 1>H, aryl, 1-5C alkyl or saturated 3-6C alkoxycarbonylalkyl; R 2>H, aryloxy, aryl mercapto, 1-5C alkyl or 1-3C hydroxyalkyl; or R 1>+R 2>3-5C alkylene; R 3>H, aryl, 1-5C alkyl, 5-7C cycloalkyl, 1-3C hydroxyalkyl, benzyl, naphthyl, or phenyl (optionally mono- to tri-substituted, by 1-5C alkyl, 1-5C alkoxy, 1-3C hydroxyalkyl, 2-5C alkoxycarbonyl, 1-3C alkylmercapto, 1-4C alkylamino, 2-8C dialkylamino, halo, trifluoromethyl, COOH, CN, OH, NO 2, NH 2, acetamido). ACTIVITY : Cerebroprotective; Cardiant; Thrombolytic. Edaravone (80 mg in isotonic solution) and/or Ozagrel sodium or Argatroban (80 mg in isotonic solution) was given intravenously, twice daily for 14 days, to patients with a diagnosis of cerebral embolism. The patients were assessed one month after the start of treatment and assigned a Modified Rankin Score of between 0 (no disease) and 6 (dead). 20 patients were given combined therapy (and 17 patients given anti-thrombus drugs only). The numbers with the specified scores for combined treatment (with numbers for anti-thrombus drugs only in brackets) as follows: score 0; 11 (6): score 1; 2 (3): score 2; 2 (3): score 3; 1 (2): score 4; 1 (0): score 5; 2 (3): score 6; 1 (0). MECHANISM OF ACTION : Platelet Aggregation Inhibitor; Thromboxane Synthase Inhibitor.

Description

    TECHNICAL FIELD
  • This invention relates to a drug comprising a combination of antithromotic agent with a pyrazolone derivative according to claim 1. In more detail, the present invention relates to the aforementioned combined drug which is useful for the remedy and/or prevention of various ischemic diseases.
    • BACKGROUND ART
  • As the remedial agent for the acute cerebral infarction, an antithrombotic agent (a thrombolytic agent, an anticoagulant, a platelet aggregation inhibitory agent) has been used hereinbefore. The remedy using such antithrombotic agent was given the priority to the treatment for the thrombus in blood vessel and the improvement of circulation. The known antithrombotic agent includes a tissue plasmigogen activator (hereinafter sometimes referred to as t-PA), a urokinase (UK), heparin, argatroban, ozagral sodium, aspirin and ticlopidine and the like.
  • However, if the antithrombotic agent is administered in large quantities or the administration of the antithrombotic agent is delayed, the conditions of the patient become worse by occurrence of the adverse effect of cerebral hemorrhage. Consequently, it cannot be said that there are few subjects to be solved.
  • Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), recently developed redical scavenger which was claimed in Japanese Patent Examined Publication (Kokoku) No. Hei. 4-35128 exhibits a free radical scavenging activity and an inhibiting activity against lipid peroxidation in cell membranes and the like. According to such activities, edaravone protects the nerve cell at the ischemic penumbra, and is able to keep the ischemic disorder to a minimum. The characteristics of edaravone includes no influence to the coagulation of blood and the aggregation of platelet and the like, and few hemorrhagic adverse effects.
  • Watanabe Y. et al. 1997, discusses drug interactions between the radical scavenger 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) and stroke medication. It is disclosed that the radical scavenging activity of MCI-186 was not influenced by argatroban or ozagrel as well as other agents.
  • Yong-Jian Jin et al., 2002, discloses the combined administration of argatroban and edaravone in a model of forebrain ischemia in gerbils. It is stated that a combination of these types of drugs may help to improve the outcomes after cerebral ischemia.
    • DISCLOSURE OF THE INVENTION
  • The subject to be solved of the present invention is to provide a drug for the remedy and/or prevention of ischemic diseases with less adverse effect, safety and having high clinical effects.
  • The present inventors have conducted various investigations to heighten the clinical effects accompanied with more high safety in the treatment of the aforementioned antithrombotic agent and found that the combination of tissue plasminogen activator with a pyrazolone derivative of the formula (I) can provides the drug for the remedy and/or prevention of ischemic diseases with less adverse effect, safety and having high clinical effects, and then completed the present invention.
  • Namely, the present invention provides a drug comprising a combination of tissue plasminogen activator with a pyrazolone derivative of the following formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
    Figure imgb0001
     (wherein R1 represents hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total; R2 represents hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or a hydroxyalkyl group having 1 to 3 carbon atoms; or R and R2 is coupled together to form an alkylene group having 3 to 5 carbon atoms; and R3 represents hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, benzyl group, a naphthyl group or phenyl group, or a phenyl group substituted with 1 to 3 substituents, which may be the same or different and selected from the group consisting of an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms in total, an alkylmercapto group having 1 to 3 carbon atoms, an alkylamino group having 1 to 4 carbon atoms, a dialkylamino group having 2 to 8 carbon atoms in total, a halogen atom, trifluoromethyl group, carboxyl group, cyano group, hydroxyl group, nitro group, amino group and acetamido group).
  • Further, the present invention provides a combined drug to administer tissue plasminogen activator and the pyrazolone derivative of the aforementioned formula (I), simultaneously, separately or sequentially.
  • Examples of antithrombotic agent are the thrombolytic agent t-PA, an anticoagulant, and a platelet aggregation inhibitory agent. An example of anticoagulants is antithrombin agent, and an example of platelet aggregation inhibitory agents is a thromboxane synthetase inhibitor. The concrete example of antithrombin agents is, for example, (2R, 4R)-4-methyl-1-[N2-((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (non-proprietary name: argatroban):
    Figure imgb0002
     and the concrete example of thromboxane synthetase inhibitors is sodium (E)-[p-(1H-imidazol-1-yl)phenyl]-2-propenoate (non-proprietary name: ozagrel sodium):
    Figure imgb0003
  • The antithrombotic agent of the present invention is t-PA. As other antithrombotic agents (2R, 4R)-4-methyl-1-[N2-((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate, and sodium (E)-[p-(1H-imidazol-1-yl)phenyl]-2-propenoate, (2R, 4R)-4-methyl-1-[N2-((RS)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate, and sodium (E)-[p-(1H-imidazol-1-yl) phenyl]-2-propenoate can be exemplified.
  • The pyrazolone derivative of the formula (I) is preferably 3-methyl-1-phenyl-2-pyrazolin-5-one.
  • The combined drugs of the present invention can be preferably used for the remedy and/or prevention of ischemic diseases. Specific examples of such ischemic diseases include various ischemic diseases or various diseases caused thereby, more specifically, various cerebral diseases, for example, cerebrovascular disorders such as cerebral infraction and stroke, impairment of brain functions due to these cerebrovascular disorders, vascular dementia, and age-related damage to cerebrovascular tissue; various heart diseases caused by myocardial ischemia such as myocardial infarction and cardiac failure; and various peripheral circulatory disorders. Preferred examples include nerve symptoms, daily behavior problems and functional disturbances, each in the acute stage of cerebral infarction; neurological symptoms (motor paralysis) in acute cerebral thrombosis (excluding lacunar infarction) within 48 hours from onset, disturbances against activities of daily living (walking, standing, sustaining the sitting position, eating); and dyskinesia associated with cerebral thrombosis (acute stage).
  • Moreover, the present invention provides a remedial agent and/or preventive agent for ischemic diseases by administering tissue plasminogen activator and the pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, simultaneously, separately or sequentially.
  • Furthermore, the present invention provides an agent for improving the function prognosis after the administration of tissue plasminogen activator which contains the pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
  • Another aspect of the present invention provides for use in a method of treating and/or preventing ischemic diseases, a pharmacologically effective amount of tissue plasminogen activator and a pharmacologically effective amount of a pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof to mammals inclusive of human beings, simultaneously, separately or sequentially.
  • Further, another aspect of the present invention provides a use of tissue plasminogen activator and a pyrazolone derivative of the aforementioned formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof for manufacturing a combined drug.
    • BEST MODES FOR CARRYING OUT THE INVENTION
  • Followings are the detailed explanations on the modes for carrying out the present invention.
  • The combined drugs of the present invention contain an antithrombotic agent and a pyrazolone derivative of the formula (I) defined in the present specification or a pharmaceutically acceptable salt thereof.
  • The antithrombotic agent used in the present invention includes a tissue plasminogen activator (t-PA). Other agents include a urokinase (UK), heparin, argatroban, ozagrel sodium, aspirin, ticlopidine and the like. Other antithrombotic agents include antithrombin agent and/or a thromboxane synthetase inhibitory agent and more concretely (2R, 4R)-4-methyl-1-[N2((RS)-3-methyl-1,2,3,4- tetrahydro-8-quinolinesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (argatroban) and/or sodium (E)-[p-(1H-imidazol-1-yl) phenyl]-2-propenoate (ozagrel sodium).
  • The compound of formula (I) used in the present invention may have the following chemical structures of formulae (I') and (I"). Consequently, the active ingredient of the present invention embraces the compounds of formulae (I') and (I")
    Figure imgb0004
  • In the formula (I), the aryl group in the definition of R1 includes phenyl group and a phenyl group substituted by a substituent such as methyl group, butyl group, methoxy group, butoxy group, chlorine atom and hydroxyl group and the like.
  • The alkyl group having 1 to 5 carbon atoms in the definition of R1, R2 and R3 includes methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group and the like.
  • The alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total in the definition of R1 includes methoxycarbonylmethyl group, ethoxycarbonylmethyl group, propoxycarbonylmethyl group, methoxycarbonylethyl group, methoxycarbonylpropyl group and the like.
  • In the definition of R2, the aryloxy group is phenoxy group, p-methylphenoxy group, p-methoxyphenoxy group, p-chlorophenoxy group, p-hydroxyphenoxy group and the like, and the arylmercapto group includes phenylmercapto group, p-methyl phenylmercapto group, p-methoxyphenylmercapto group, p-chlor phenylmercapto group, p-hydroxyphenylmercapto group and the like.
  • The hydroxyalkyl group having 1 to 3 carbon atoms in the definition of R2 and R3 includes hydroxymethyl group, 2-hydroxyethyl group, 3-hydroxypropyl group and the like. The cycloalkyl group having 5 to 7 carbon atoms in the definition of R3 is cyclopentyl group, cyclohexyl group, cycloheptyl group and the like.
  • In the substituent of the phenyl group in the definition of R3, the alkoxy group having 1 to 5 carbon atoms includes methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, pentyloxy group and the like, the alkoxycarbonyl group having 2 to 5 carbon atoms in total includes methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, butoxycarbonyl group and the like, the alkylmercapto group having 1 to 3 carbon atoms includes methylmercapto group, ethylmercapto group, propylmercapto group and the like, the alkylamino group having 1 to 4 carbon atoms includes methylamino group, ethylamino group, propylamino group, butylamino group and the like, and the dialkylamino group having 2 to 8 carbon atoms in total includes dimethylamino group, diethylamino group, dipropylamino group, dibutylamino group and the like.
  • The Examples of the compounds of formula (I) used in the present invention include, for example, the following compounds:
    • 3-Methyl-1-phenyl-2-pyrazolin-5-one,
    • 3-Methyl-1-(2-methylphenyl)-2-pyrazolin-5-one,
    • 3-Methyl-1-(3-methylphenyl)-2-pyrazolin-5-one,
    • 3-Methyl-1-(4-methylphenyl)-2-pyrazolin-5-one,
    • 3-Methyl-1-(3,4dimethylphenyl)-2-pyrazolin-5-one,
    • 1-(4-Ethylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 3-Methyl-1-(4-propylphenyl)-2-pyrazolin-5-one,
    • 1-(3-Butylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Trifluoromethylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Trifluoromethylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(2-Methoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Methoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Methoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3,4-Dimethoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Ethoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 3-Methyl-1-(4-propoxyphenyl)-2-pyrazolin-5-one,
    • 1-(4-Butoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(2-Chlorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Chlorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Chlorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3,4-Dichlorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Bromophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Fluorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Chloro-4-methylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Methylmercaptophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Methylmercaptophenyl)-3-methyl-2-pyrazolin-5-one,
    • 4-(3-methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid,
    • 1-(4-Ethoxycarbonylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Nitrophenyl)-3-methyl-2-pyrazolin-5-one,
    • 3-Ethyl-1-phenyl-2-pyrazolin-5-one,
    • 1-Phenyl-3-propyl-2-pyrazolin-5-one,
    • 1,3-Diphenyl-2-pyrazolin-5-one,
    • 1-Phenyl-3-(p-tolyl)-2-pyrazolin-5-one,
    • 1-(4-Methoxyphenyl)-3-phenyl-2-pyrazolin-5-one,
    • 1-(4-Chlorophenyl)-3-phenyl-2-pyrazolin-5-one,
    • 3,4-Dimethyl-1-phenyl-2-pyrazolin-5-one,
    • 4-Isobutyl-3-methyl-1-phenyl-2-pyrazolin-5-one,
    • 4-(2-Hydroxyethyl)-3-methyl-1-phenyl-2-pyrazolin-5-one,
    • 3-Methyl-4-phenoxy-1-phenyl-2-pyrazolin-5-one,
    • 3-Methyl-4-phenylmercapto-1-phenyl-2-pyrazolin-5-one,
    • 3,3',4,5,6,7-Hexahydro-2-phenyl-2H-indazol-3-one,
    • 3-(Ethoxycarbonylmethyl)-1-phenyl-2-pyrazolin-5-one,
    • 1-Phenyl-2-pyrazolin-5-one,
    • 3-Methyl-2-pyrazolin-5-one,
    • 1,3-Dimethyl-2-pyrazolin-5-one,
    • 1-Ethyl-3-methyl-2-pyrazolin-5-one,
    • 1-Butyl-3-methyl-2-pyrazolin-5-one,
    • 1-(2-Hydroxyethyl)-3-methyl-2-pyrazolin-5-one,
    • 1-Cyclohexyl-3-methyl-2-pyrazolin-5-one,
    • 1-Benzyl-3-methyl-2-pyrazolin-5-one,
    • 1-(α-Naphthyl)-3-methyl-2-pyrazolin-5-one,
    • 1-Methyl-3-phenyl-2-pyrazolin-5-one,
    • 3-Methyl-1-(4-methylphenyl)-2-pyrazolin-5-one,
    • 1-(4-Butylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Methoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Butoxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Chlorophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Hydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3,4-Dihydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(2-Hydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3-Hydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Hydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(3,4-Dihydroxyphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Hydroxyphenyl)-3-phenyl-2-pyrazolin-5-one,
    • 1-(4-Hydroxymethylphenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Aminophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Methylaminophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Ethylaminophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Butylaminophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(4-Dimethylaminophenyl)-3-methyl-2-pyrazolin-5-one,
    • 1-(Acetoamidophenyl)-3-methyl-2-pyrazolin-5-one, and
    • 1-(4-Cyanophenyl)-3-methyl-2-pyrazolin-5-one.
  • As the active ingredient of the drug of the present invention, a physiologically acceptable salt as well as a free form of the compound of formula (I) can be used. Such physiologically acceptable salt includes a salt with a mineral acid such as hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid and the like; a salt of an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, acetic acid, glycolic acid, glucuronic acid, maleic acid, fumaric acid, oxalic acid, ascorbic acid, citric acid, salicylic acid, nicotinic acid, tartaric acid and the like; a salt with an alkaline metal such as sodium, potassium and the like, and a salt with an amine such as ammonia, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglutamine, L-glutamine and the like. Further, a salt with an amino acid such as glycine can be used.
  • The active ingredient of the drug of the present invention can be used as a hydrate of the compound of the aforementioned formula (I) or a physiologically acceptable salt thereof, and a solvate of the compound of the aforementioned formula (I) or a physiologically acceptable salt thereof. A type of the solvent used to form a solvate is not specifically limited. For example, methanol, ethanol, ether, dioxane, tetrahydrofuran can be exemplified. In case that the compounds of the aforementioned formula (I) have one or more asymmetric carbons based on the type of the substituent, there may exist a stereoisomer such as an optical isomer or a diastereoisomer. As the active ingredient of the drug of the present invention, a stereoisomer in a pure form, any mixture of stereoisomers, a racemate and the like may also be used.
  • The compounds of formula (I) used in the present invention are known compounds and disclosed, for example, in Japanese Patent Examined Publication (Kokoku) No. Hei. 5-31523 , Japanese Patent Examined Publication (Kokoku) No. Hei. 5-35128 and the like.
  • The dose of tissue plasminogen activator used in the present invention is usually 0.01 to 100 mg/kg per day, preferably 0.1 to 10 mg/kg per day for the parenteral administration, and 1 to 1,000 mg/kg per day, preferably 0.5 to 50 mg/kg per day for the oral administration. The aforementioned dose can be preferably administered once to three times a day. The dose mentioned above may be suitably varied depending upon the age, and the severity and condition of the diseases.
  • The dose of the pyrazolone derivative of the formula (I) used in the present invention is usually 0.01 to 100 mg/kg per day, preferably 0.1 to 10 mg/kg per day for the parenteral administration, and 1 to 1,000 mg/kg per day, preferably 0.5 to 50 mg/kg per day for the oral administration. The aforementioned dose can be preferably administered once to three times a day. The dose mentioned above may be suitably varied depending upon the age, and the severity and condition of the diseases.
  • The combined drug of the present invention may be administered separately by formulating each of the antithrombotic agent and the pyrazolone derivatives of formula (I) into each of drugs. The antithrombotic agent and the pyrazolone derivative of formula (I) can be administered simultaneously, separately or sequentially. The antithrombotic agent and the pyrazolone derivative of formula (I) can be also administered by formulating them into a single formulation.
  • In the present invention, the antithrombotic agent and the pyrazolone derivative of formula (I), a physiologically acceptable salt thereof, or a hydrate or solvate thereof can be administered themselves, but usually and preferably administered by preparing a pharmaceutical composition containing the aforementioned substance as the active ingredient and a pharmacologically and pharmaceutically acceptable additive.
  • Such pharmacologically and pharmaceutically acceptable additive include, for example, an excipient, a disintegrator or a disintegration adjuvant agent, a binder, a lubricant, a coating agent, a pigment, a diluent, a base, a solvent or a solubilizer, an isotonic agent, a pH adjusting agent, a stabilizer, a propellant, and an adhesive.
  • As the additives of the pharmaceutical composition suitable to the oral administration, for example, an excipient such as glucose, lactose, D-mannitol, starch, or crystalline cellulose and the like; a disintegrator or a disintegration adjuvant agent such as carboxymethylcellulose, starch, or calcium carboxymethylcellulose and the like; a binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, or gelatin and the like; a lublicant such as magnesium stearate or talc and the like; a coating agent such as hydroxypropylmethylcellulose, sucrose, polyethyleneglycol, or titanium oxide and the like; or a base such as vaseline, liquid paraffin, polyethyleneglycol, gelatin, kaolin, glycerin, purified water or a hard fat can be used.
  • For a pharmaceutical composition suitable for an injection or a drip infusion, there can be used an additive, for example, a solvent or a solubilizer such as distilled water for injection, physiological saline or propylene glycol that can constitute an aqueous injection or an injection that is dissolved when used; an isotonic agent such as glucose, sodium chloride, D-mannitol, glycerin and the like; or a pH adjusting agent such as an inorganic acid, an organic acid, an inorganic base or an organic base and the like.
  • The form of the drug of the present invention is not specifically limited, and may be any of the various forms that can be applied to the person skilled in the art. As the drug appropriate for oral administration, for example, tablets, powders, granules, hard gelatin capsules, suppositories, or troches and the like can be prepared by using solid additives for pharmaceutical preparation, and for example, syrups, emulsions, soft gelatin capsules and the like can be prepared by using liquid additives for pharmaceutical preparation. As the pharmaceutical preparation suitable for parenteral administration, injections, drip infusions, inhalants, percutaneous absorbents, trans-mucosal absorbents and the like can be prepared. As a protective agent for the brain (infusion drip) containing the compound of the aforementioned formula (I) as the active ingredient has already been clinically used (under non-proprietary name: "Edaravone", and the commercial name: "Radicut"; manufactured and distributed by Mitsubishi Pharma Corporation), the aforementioned commercially available drug can be used as it is as the pyrazolone derivative of formula (I) for the combined drug of the present invention.
  • The present invention will be explained in more detail by the following examples. The scope of the present invention is not limited by the following examples.
  • In the following examples, Grtpa (registered trademark; manufactured and distributed by Mitsubishi Pharma Corporation), Xanbon (registered trademark; manufactured and distributed by Kissei Pharmaceutical Co., Ltd.) and Novastan (registered trademark; manufactured and distributed by Mitsubishi Pharma Corporation) can be used as t-PA, ozagrel sodium, argatroban, respectively, but any pharmaceutical preparations containing t-PA, ozagrel sodium, argatroban as the active ingredient which are regardless of the manufacturing or distributing company can be used.
    • EXAMPLE Synthetic Example: Synthesis of 3-methyl-phenyl-2-pyrazolin-5-one (hereinafter referred to as edaravone)
  • 13.0 g of ethyl acetacetate and 10.8 g of phenylhydrazine were added to 50 ml of ethanol, and the mixture was stirred under reflux for 3 hours. After cooling the reaction solution by standing, the precipitated crystals were collected by filtration and recrystallized from ethanol to give 11.3 g of the title compound as a colorless crystal.
    • Example 1 (Test method)
  • Via a cannula inserted into the femoral vein of each Wistar rat anesthetized with urethane (1.2 g/kg, i.p.), 1 mg/kg (1 mg = 580000 IU; 4mL/kg, 1 mL/hr) of physiological saline or t-PA was constantly infused. Fifty five minutes after the constant fusion was started, 3 mg of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) or physiological saline was administered intravenously. Five minutes after that, the tail was transected at 2 mm from its tip immediately by using a razor. Every 15 seconds, the blood from the tail was blotted with a filter paper and the time until bleeding ceased was measured for up to 30 minutes.
    • (Test results)
  • The results of the influence of t-PA on the bleeding time are shown in Table 1 (all the numerical values in this table indicate average ± S.E.).
  • It has been recognized that compared with the control group (physiological saline), the t-PA-administered group prolonged the bleeding time significantly. The t-PA- and edaravone-administered group did not have a significant influence on the bleeding time, compared with the edaravone-administered group. From this, it is apparent that edaravone can be used in combination with t-PA without causing any side effects. Table 1: Influence of t-PA on the bleeding time
    Medicament Number of cases Bleeding time (min)
    Control 10 9.33 ± 2.36
    Edaravone, 3 mg/kg 10 11.55 ± 2.31
    t-PA, 1 mg/kg (1 mg = 580000 IU) 10 17.70 ± 2.85 *
    Edaravone, 3 mg/kg + t-PA, 1 mg/kg 10 15.40 ± 2.77
    P<0.05 (t-test, vs control)
    • Comparative Example 1 (Test method)
  • As shown in Table 2, 37 patients diagnosed as cerebral infarction were classified and administered with a medicament. Administration amount and method are shown below.
  • Sodium ozagrel: 80 mg of sodium ozagrel was dissolved in an adequate amount of an electrolyte solution or carbohydrate solution and the resulting solution was intravenously administered constantly for 2 weeks, twice daily, that is, in the morning and evening, each over 2 hours.
  • Argatroban: For the first two days, 60 mg/120 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused constantly over 24 hours. For the following 5 days, 10 mg/20 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused twice daily, that is, in the morning and evening, each over 3 hours.
  • Sodium ozagrel + edaravone: 80 mg of sodium ozagrel was dissolved in an adequate amount of an electrolyte solution or carbohydrate solution and the resulting solution was intravenously administered constantly for 2 weeks, twice daily, that is, in the morning and evening, each over 2 hours. At the same time, 30 mg/20 ml of edaravone was diluted with an adequate amount of physiological saline and the resulting solution was intravenously infused for 2 weeks, twice daily, that is, in the morning and evening, each over 20 minutes.
  • Argatroban + edaravone: For the first two days, 60 mg/120 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused constantly over 24 hours. For the following 5 days, 10 mg/20 ml of argatroban was diluted with an adequate amount of a transfusion fluid and the resulting solution was intravenously infused twice daily, that is, in the morning and evening, each over 3 hours; and at the same time, 30 mg/20 ml of edaravone was diluted with an adequate amount of physiological saline and the resulting solution was intravenously infused for 2 weeks twice daily, that is, in the morning and evening, each over 30 minutes.
    • (Test results)
  • On the leaving day of the hospital within 1 month after the administration was started (after one month when the patient was in hospital), evaluation results of the function prognosis in accordance with the modified ranking scale are shown in Table 2. Table 2
    Grade 0 1 2 3 4 5 6 Total
    OZA* 5 2 1 1 0 0 0 9
    NOV* 1 1 2 1 0 3 0 8
    Antithrombotic agent alone 6 3 3 2 0 3 0 17
    Edaravone + OZA * 2 1 0 1 1 0 1 6
    Edaravone + NOV * 9 1 2 0 0 2 0 14
    Edaravone + antithrombotic agent 11 2 2 1 1 2 1 20
    *: OZA means sodium ozagrel and NOV means argatroban.
  • In the above-described table, what the meaning of grade will be explained briefly. Grade 0: no symptoms, Grade 1: some symptoms but non-significant disability (able to carry out all daily activities and affairs), Grade 2: slight disability (unable to carry out all previous activities but able to look after own affairs without assistance),
    Grade 3: moderate disability (requiring some help, but able to walk without assistance), Grade 4: relatively severe disability (requiring assistance for walk or daily activities),
    Grade 5: very severe disability (bedridden, incontinence and requiring constant nursing
    care and attention), Grade 6: death.
    • (Comparative Example 2)
  • Evaluation results of edaravone, when administered alone, in accordance with the modified ranking scale are included in Therapeutic Research, Vol. 19(4), 1333-1345, 1998.
    Evaluation method and results: Edaravone (30 mg/20 ml) diluted with 100 ml of physiological saline was intravenously infused to 8 patients in the acute stage of cerebral infarction constantly for 14 days twice daily (morning and evening), each over 30 minutes. During the administration term of this medicament, administration of another medicament which might have an influence on the drug efficacy evaluation was avoided. Evaluation was made in accordance with the modified ranking scale three months after the initiation of the administration or upon discharge of the patient from the hospital within three months after the initiation of administration. Results are as shown below.
    Grade 0 1 2 3 4 5 6 Total
    Administration of edaravone alone 0 2 3 0 3 0 0 8
    Grade 1: Some symptoms but non-significant disability
    Grade 2: Slight disability
    Grade 4: Relatively severe disability
  • There is no difference between Comparative Example 1 and Comparative Example 2 except for the time of evaluation based on the modified ranking scale, that is, within one month after the initiation of administration in Comparative Example 1, while within three months in Comparative Example 2. These results obtained in Comparative Example 1 and 2 were therefore compared, which has revealed that a ratio of Grade 0 was 35.3% when the antithrombotic agent was used alone and 0% when edaravone was used alone, while it was 55.0% when the antithrombotic agent and edaravone were used in combination. This suggests that combined use of the antithrombotic agent and edaravone brings not merely an additive effect but a synergistic effect, and function prognosis is good.
    • INDUSTRIAL APPLICABILITY
  • By combining of antithrombotic agent issue plasminogen activator, the pyrazolone derivatives used in the present invention can enhance the suppressing effects to the function disorder of the antithrombotic agent, suppress the aggravate of the symptoms caused by the side effects of the antithrombotic agent and reperfusion injuries to a minimum, and then bring the more safe clinical effects.
  • The combined drugs of the present invention are useful as the preventive and/or remedial medicament for various ischemic diseases or various diseases caused thereby, specifically various cerebral diseases, for example, cerebrovascular disorders such as cerebral infarction and stroke, impairment of brain functions due to these cerebrovascular disorders, vascular dementia, age-related damage to cerebrovascular tissues; various heart diseases caused by myocardial ischemia such as myocardial infarction and cardiac failure; and various peripheral circulatory disorders.

Claims (8)

  1. A drug which comprises a combination of a tissue plasminogen activator with a pyrazolone derivative of the following formula (I):
    Figure imgb0005
     (wherein R1 represents hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total; R2 represents hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or a hydroxyalkyl group having 1 to 3 carbon atoms; or R1 and R2 is coupled together to form an alkylene group having 3 to 5 carbon atoms; and R3 represents hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, benzyl group, a naphthyl group or phenyl group, or a phenyl group substituted with 1 to 3 substituents, which may be the same or different and selected from the group consisting of an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms in total, an alkylmercapto group having 1 to 3 carbon atoms, an alkylamino group having 1 to 4 carbon atoms, a dialkylamino group having 2 to 8 carbon atoms in total, a halogen atom, trifluoromethyl group, carboxyl group, cyano group, hydroxyl group, nitro group, amino group and acetamido group), or pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
  2. The combined drug according to Claim 1, wherein the tissue plasminogen activator and the pyrazolone derivative or pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof according to Claim 1 are administered simultaneously, separately or sequentially.
  3. The combined drug according to claim 1 or 2, wherein the pyrazolone derivative of the formula (I) is 3-methyl-1-phenyl-2-pyrazolin-5-one.
  4. The combined drug according to any one of Claims 1 to 3 which is for use in a method of remedy and/or prevention of an ischemic disease.
  5. A remedial agent and/or preventive agent for an ischemic disease, which is for administering a tissue plasminogen activator and 3-methyl-1-phenyl-2-pyrazolin-5-one simultaneously, separately or sequentially.
  6. A remedial agent and/or preventive agent for an ischemic disease, which is for administering a tissue plasminogen activator and the pyrazolone derivative or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof according to Claim 1 simultaneously, separately or sequentially.
  7. An agent for improving the function prognosis after the administration of a tissue plasminogen activator, which contains the pyrazolone derivative or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof according to Claim 1.
  8. Use of a combination of a tissue plasminogen activator with a pyrazolone derivative of the following formula (I):
    Figure imgb0006
     (wherein R1 represents hydrogen atom, an aryl group, an alkyl group having 1 to 5 carbon atoms or an alkoxycarbonylalkyl group having 3 to 6 carbon atoms in total; R2 represents hydrogen atom, an aryloxy group, an arylmercapto group, an alkyl group having 1 to 5 carbon atoms or a hydroxyalkyl group having 1 to 3 carbon atoms; or R1 and R2 is coupled together to form an alkylene group having 3 to 5 carbon atoms; and R3 represents hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a cycloalkyl group having 5 to 7 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, benzyl group, a naphthyl group or phenyl group, or a phenyl group substituted with 1 to 3 substituents, which may be the same or different and selected from the group consisting of an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms in total, an alkylmercapto group having 1 to 3 carbon atoms, an alkylamino group having 1 to 4 carbon atoms, a dialkylamino group having 2 to 8 carbon atoms in total, a halogen atom, trifluoromethyl group, carboxyl group, cyano group, hydroxyl group, nitro group, amino group and acetamido group), or pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof for the manufacture of a medicament for remedy and/or prevention of an ischemic disease.
EP02760833A 2001-09-14 2002-09-13 Drugs comprising combination of antithrombotic agent with pyrazolone derivative Expired - Lifetime EP1437137B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001279645 2001-09-14
JP2001279645 2001-09-14
JP2001365032 2001-11-29
JP2001365032 2001-11-29
PCT/JP2002/009425 WO2003024445A1 (en) 2001-09-14 2002-09-13 Drugs comprising combination of antithrombotic agent with pyrazolone derivative

Publications (3)

Publication Number Publication Date
EP1437137A1 EP1437137A1 (en) 2004-07-14
EP1437137A4 EP1437137A4 (en) 2006-05-10
EP1437137B1 true EP1437137B1 (en) 2008-12-31

Family

ID=26622230

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02760833A Expired - Lifetime EP1437137B1 (en) 2001-09-14 2002-09-13 Drugs comprising combination of antithrombotic agent with pyrazolone derivative

Country Status (10)

Country Link
US (1) US8183206B2 (en)
EP (1) EP1437137B1 (en)
JP (2) JP4521186B2 (en)
KR (1) KR20040044514A (en)
CN (1) CN100398104C (en)
AT (1) ATE418983T1 (en)
CA (1) CA2460141C (en)
DE (1) DE60230655D1 (en)
ES (1) ES2318036T3 (en)
WO (1) WO2003024445A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004331653A (en) * 2003-04-14 2004-11-25 Mitsubishi Pharma Corp Prophylactic and/or remedial agent for pain
JP2004346067A (en) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp Medicinal agent for extending time for treatment with anti-thrombus agent
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
CN101524352A (en) 2008-03-04 2009-09-09 江苏先声药物研究有限公司 Composition containing 3-methyl-1-phenyl-2-pyrazoline-5-ketone
MX2011003438A (en) 2008-11-20 2011-07-29 Teikoku Pharma Usa Inc Pyrazalone derivative formulations.
CN106420688B (en) * 2016-10-08 2017-11-10 西北大学 IDHP prepares the application of prevention and treatment coronary atherosclerosis disease medicine
EP3694839B1 (en) * 2017-10-13 2022-07-27 Treeway TW001 B.V. Edaravone salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK169672B1 (en) 1985-05-20 1995-01-09 Mitsubishi Chem Ind Pharmaceutical preparations containing pyrazolone derivatives as active ingredient and the use of pyrazolone derivatives for the preparation of pharmaceutical preparations
JPH03130028A (en) 1989-08-08 1991-06-03 Nippon Alum Mfg Co Ltd Feeding apparatus
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia

Also Published As

Publication number Publication date
JPWO2003024445A1 (en) 2004-12-24
JP4521186B2 (en) 2010-08-11
US8183206B2 (en) 2012-05-22
CN100398104C (en) 2008-07-02
US20050009896A1 (en) 2005-01-13
JP5081890B2 (en) 2012-11-28
CA2460141C (en) 2012-01-10
ES2318036T3 (en) 2009-05-01
EP1437137A1 (en) 2004-07-14
WO2003024445A1 (en) 2003-03-27
CN1555261A (en) 2004-12-15
JP2010043132A (en) 2010-02-25
EP1437137A4 (en) 2006-05-10
CA2460141A1 (en) 2003-03-27
DE60230655D1 (en) 2009-02-12
ATE418983T1 (en) 2009-01-15
KR20040044514A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
JP5081890B2 (en) Combination drugs of antithrombotic drugs and pyrazolone derivatives
JP2004536807A (en) How to treat glaucoma V
JP5469707B2 (en) Pyrazolone compounds useful for the treatment of cerebrovascular disorders associated with cerebral infarction
JPWO2006126625A1 (en) Medicine containing pyrazolone derivative
JP4713859B2 (en) Treatment and / or prevention agent for mitochondrial encephalomyopathy
JP4418621B2 (en) Pharmaceuticals for the prevention and / or treatment of lung disorders
US7312239B2 (en) Medicament for prevention and/or therapy of arterial wall disorder
JP2006096664A (en) Hepatic fibrosis inhibitor
WO2003078401A1 (en) Preventive and/or therapeutic agent for hypoxic ischemic brain disorder
JP2004115508A (en) Medicine for improving function of thermally injured skin tissue
JP2004346067A (en) Medicinal agent for extending time for treatment with anti-thrombus agent
JP2005162749A (en) Agent for preventing and/or treating internal carotid artery occlusion or internal carotid artery constriction
WO2003064395A1 (en) Preventive or therapeutic agents for neurodegenerative diseases
JP2004331653A (en) Prophylactic and/or remedial agent for pain
JP2004002400A (en) Medicine for brain protection and/or brain function normalization in slight hypothermia
JPWO2003066051A1 (en) Preventive and / or therapeutic agent for myocardial dysfunction
JP2004123713A (en) Medicine for preventing and/or treating sudden deafness
JP2004123700A (en) Peroxynitrite-eliminating agent
JP2008037753A (en) Therapeutic and/or preventive agent for pruritus
JP2004277315A (en) Anti-tumor agent
JP2005314348A (en) Drug for treatment of facial paralysis
JP2003267871A (en) Radiation hazard-preventing agent
JPWO2004013107A1 (en) Medicament for prevention and / or treatment of injury due to spinal cord injury
JPWO2005012255A1 (en) Treatment for inflammatory joint diseases
JP2004532249A (en) Method for treating glaucoma VI

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040407

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/415 20060101AFI20030401BHEP

Ipc: A61K 31/4545 20060101ALI20060217BHEP

Ipc: A61K 45/00 20060101ALI20060217BHEP

Ipc: A61P 7/02 20060101ALI20060217BHEP

Ipc: A61P 9/10 20060101ALI20060217BHEP

Ipc: C07D 231/22 20060101ALI20060217BHEP

Ipc: C07D 231/56 20060101ALI20060217BHEP

Ipc: C07D 231/26 20060101ALI20060217BHEP

Ipc: C07D 231/28 20060101ALI20060217BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060323

17Q First examination report despatched

Effective date: 20070914

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITSUBISHI TANABE PHARMA CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 60230655

Country of ref document: DE

Date of ref document: 20090212

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2318036

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090601

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090401

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140911

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20140812

Year of fee payment: 13

Ref country code: GB

Payment date: 20140910

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140912

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140906

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60230655

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150913

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150913

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160401

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20161026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150914